Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Translational Neurodegeneration
Published in: Translational Neurodegeneration 1/2015

Open Access 01-12-2015 | Research

Clinical management and associated costs for moderate and severe Alzheimer’s disease in urban China: a Delphi panel study

Authors: Xin Yu, Shengdi Chen, Xiaochun Chen, Jianjun Jia, Chunhou Li, Cong Liu, Mondher Toumi, Dominique Milea

Published in: Translational Neurodegeneration | Issue 1/2015

Login to get access

Abstract

Background

Healthcare resource utilisation for Alzheimer’s disease (AD) in China is not well understood. This Delphi panel study aimed to describe the clinical management pathways for moderate and severe AD patients in urban China and to define the amount and cost of healthcare resources used.

Methods

A panel of 11 experts was recruited from urban China to participate in two rounds of preparatory interviews. In the first round, 9 physicians specialised in dementia gave a qualitative description of the clinical management of AD patients. In the second round, 2 hospital administrators were asked about the cost of AD management and care. Results from the interviews were discussed by the experts in a Delphi panel meeting, where consensus was reached on quantitative aspects of AD management, including the rate of healthcare resource utilisation, the respective unit costs and caregiving time.

Results

Interviewees reported that mild AD is under-recognised in China; most patients are diagnosed with moderate to severe AD. Loss of independence and agitation/aggression are the main drivers for healthcare resource utilisation and contribute to a heavier caregiver burden. It was estimated that 70 % moderate AD patients are independent/non-aggressive at the time of diagnosis, 15 % are independent/aggressive, 10 % are dependent/non-aggressive, and 5 % are dependent/aggressive. Dependent/aggressive AD patients are more likely to be hospitalised (70–90 %) than accepted in a nursing home (0–20 %), while the opposite is true for dependent/non-aggressive patients (5–35 % for hospitalisation vs. 80 % for nursing home). Independent AD patients require 1–3 hours/day of caregiver time, while dependent patients can require up to 12–15 hours/day. Experts agreed that AD complicates the management of age-related comorbidities, found in 70–80 % of all AD patients, increasing the frequency and cost of hospitalisation.

Conclusions

The Delphi panel approach was an efficient method of gathering data about the amount of healthcare resources used and associated costs for moderate and severe AD patients in urban China. The results of this study provide a useful source of information for decision makers to improve future healthcare policies and resource planning, as well as to perform economic evaluations of AD therapies.
Literature
1.
Robert PH, Verhey FR, Byrne EJ, Hurt C, De Deyn PP, Nobili F, et al. Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. Eur Psychiatry. 2005;20(7):490–6.CrossRefPubMed
2.
Aalten P, Jolles J, de Vugt M, Verhey F. The influence of neuropsychological functioning on neuropsychiatric problems in dementia. J Neuropsychiatry Clin Neurosci. 2007;19(1):50–6.CrossRefPubMed
3.
4.
Thies W, Bleiler L. 2013 Alzheimer’s disease facts and figures. Alzheimers Dement. 2013;9(2):208–45.CrossRef
5.
Chan KY, Wang W, Wu JJ, Liu L, Theodoratou E, Car J, et al. Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990–2010: a systematic review and analysis. Lancet. 2013;381(9882):2016–23.CrossRefPubMed
6.
Dillon C, Serrano CM, Castro D, Leguizamón PP, Heisecke SL, Taragano FE. Behavioral symptoms related to cognitive impairment. Neuropsychiatr Dis Treat. 2013;9:1443.PubMedCentralCrossRefPubMed
7.
Sun X, Jin L, Ling P. Review of drugs for Alzheimer’s disease. Drug Discov Ther. 2012;6(6):285–90.PubMed
8.
9.
Chen R, Hu Z, Chen R-L, Ma Y, Zhang D, Wilson K. Determinants for undetected dementia and late-life depression. Br J Psychiatry. 2013;203(3):203–8.CrossRefPubMed
10.
Chen S, Boyle LL, Conwell Y, Chiu H, Li L, Xiao S. Dementia care in rural China. Ment Health Fam Med. 2013;10(3):133–41.PubMedCentralPubMed
11.
Wimo A, Winblad B, Jönsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement. 2010;6(2):98–103.CrossRefPubMed
12.
Leicht H, Heinrich S, Heider D, Bachmann C, Bickel H, van den Bussche H, et al. Net costs of dementia by disease stage. Acta Psychiatr Scand. 2011;124(5):384–95.CrossRefPubMed
13.
Quentin W, Riedel‐Heller S, Luppa M, Rudolph A, König HH. Cost‐of‐illness studies of dementia: a systematic review focusing on stage dependency of costs. Acta Psychiatr Scand. 2010;121(4):243–59.CrossRefPubMed
14.
15.
Tang B, Harary E, Kurzman R, Mould-Quevedo JF, Pan S, Yang J, et al. Clinical characterization and the caregiver burden of dementia in China. Value Health. 2013;Regional Issue 2(1):118–26.CrossRef
16.
Wang J, Xiao LD, He G-P, Ullah S, De Bellis A. Factors contributing to caregiver burden in dementia in a country without formal caregiver support. Aging Ment Health. 2014;18(8):986–96.CrossRefPubMed
17.
Mould-Quevedo JF, Tang B, Harary E, Kurzman R, Pan S, Yang J, et al. The burden of caring for dementia patients: caregiver reports from a cross-sectional hospital-based study in China. Expert Rev Pharmacoecon Outcomes Res. 2013;13(5):663–73.CrossRefPubMed
18.
Allegri RF, Butman J, Arizaga RL, Machnicki G, Serrano C, Taragano FE, et al. Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina. Int Psychogeriatr. 2007;19(04):705–18.CrossRefPubMed
19.
Beeri MS, Werner P, Adar Z, Davidson M, Noy S. Economic cost of Alzheimer disease in Israel. Alzheimer Dis Assoc Disord. 2002;16(2):73–80.CrossRefPubMed
20.
Jönsson L, Jönhagen ME, Kilander L, Soininen H, Hallikainen M, Waldemar G, et al. Determinants of costs of care for patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 2006;21(5):449–59.CrossRefPubMed
21.
Lowin A, Knapp M, McCrone P. Alzheimer’s disease in the UK: comparative evidence on cost of illness and volume of health services research funding. Int J Geriatr Psychiatry. 2001;16(12):1143–8.CrossRefPubMed
22.
Rigaud A-S, Bayle C, Fagnani F, Latour F, Traykov L, Forette F. Patients with Alzheimer’s disease living at home in France: costs and consequences of the disease. J Geriatr Psychiatry Neurol. 2003;16(3):140–5.CrossRefPubMed
23.
Zencir M, Kuzu N, Beşer NG, Ergin A, Catak B, Şahiner T. Cost of Alzheimer’s disease in a developing country setting. Int J Geriatr Psychiatry. 2005;20(7):616–22.CrossRefPubMed
24.
Zhu C, Scarmeas N, Torgan R, Albert M, Brandt J, Blacker D, et al. Clinical features associated with costs in early AD baseline data from the predictors study. Neurology. 2006;66(7):1021–8.CrossRefPubMed
25.
Wang G, Cheng Q, Zhang S, Bai L, Zeng J, Cui P-J, et al. Economic impact of dementia in developing countries: an evaluation of Alzheimer-type dementia in Shanghai. China J Alzheimers Dis. 2008;15(1):109–15.PubMed
26.
27.
Keeney S, Hasson F, McKenna HP. A critical review of the Delphi technique as a research methodology for nursing. Int J Nurs Stud. 2001;38(2):195–200.CrossRefPubMed
28.
Hu S, Yu X, Chen S, Clay E, Toumi M, Milea D. Memantine for treatment of moderate or severe Alzheimer’s disease patients in urban China: clinical and economic outcomes from a health economic model. Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):565–78.CrossRefPubMed
29.
Bidzan L, Bidzan M, Pąchalska M. Aggressive and impulsive behavior in Alzheimer’s disease and progression of dementia. Med Sci Monit. 2012;18(3):CR182.PubMedCentralCrossRefPubMed
30.
Sinha IP, Smyth RL, Williamson PR. Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. PLoS Med. 2011;8(1):e1000393.PubMedCentralCrossRefPubMed
31.
Miller MA, Sutter RW, Strebel PM, Hadler SC. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA. 1996;276(12):967–71.CrossRefPubMed
32.
Guest JF, Hart WM, Cookson RF. Cost analysis of palliative care for terminally ill cancer patients in the UK after switching from weak to strong opioids. Pharmacoeconomics. 1998;14(3):285–97.CrossRefPubMed
33.
Thaulow E, Jorgensen B, Doyle JJ, Casciano R, Casciano J, Kopp Z, et al. A pharmacoeconomic evaluation of results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES) in Norway and Canada. Int J Cardiol. 2002;84(1):23–30.CrossRefPubMed
34.
Kobelt G, Canning DA, Hensle TW, LÄCKGREN G. The cost-effectiveness of endoscopic injection of dextranomer/hyaluronic acid copolymer for vesicoureteral reflux. J Urol. 2003;169(4):1480–5.CrossRefPubMed
35.
Le Pen C, Levy E, Ravily V, Beuzen J, Meurgey F. The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine vs. tricyclics. J Affect Disord. 1994;31(1):1–18.CrossRefPubMed
36.
Yuen PP, Gould D, Cheng M. Rationing hospital services in Hong Kong: priority setting by clinicians using the Delphi method. Health Serv Manage Res. 2002;15(1):1–13.CrossRefPubMed
37.
Zhao Z, Cheng J, Xu S, Hou W, Richardus J. A quality assessment index framework for public health services: a Delphi study. Public Health. 2015;129(1):43–51.CrossRefPubMed
38.
Wong WC, Ho PS, Liang J, Holroyd EA, Lam CL, Pau AM. Road to better health and integration: a Delphi study on health service models for Hong Kong migrants. Int J Equity Health. 2014;13(1):127.PubMedCentralCrossRefPubMed
39.
Zhong S, Clark M, Hou X-Y, Zang Y, FitzGerald G. Development of key indicators of hospital resilience: a modified Delphi study. J Health Serv Res Policy. 2014;1355819614561537.
40.
Lv J, Liu M, Jiang Y, Li L-M. Prevention and control of major non-communicable diseases in China from 1990 to 2009: results of a two-round Delphi survey. Glob Health Action. 2013;6:20004.PubMed
41.
Ferri C, Chisholm D, Van Ommeren M, Prince M. Resource utilisation for neuropsychiatric disorders in developing countries. Soc Psychiatry Psychiatr Epidemiol. 2004;39(3):218–27.CrossRefPubMed
42.
Yang L, Li M, Tao LB, Zhang M, Nicholl MD, Dong P. Cost‐effectiveness of long‐acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China. Value Health. 2009;12(s3):S66–9.CrossRefPubMed
43.
Liu Y-wJ, Lai K-yC, Dai D, Ting S, Choi K. Attitudes in the management of patients with dementia: comparison in doctors with and without special training. East Asian Arch Psychiatry. 2013;23(1):13–20.PubMed
44.
Boise L, Neal MB, Kaye J. Dementia assessment in primary care: results from a study in three managed care systems. J Gerontol A Biol Sci Med Sci. 2004;59(6):M621–6.CrossRefPubMed
45.
Boustani M, Callahan CM, Unverzagt FW, Austrom MG, Perkins AJ, Fultz BA, et al. Implementing a screening and diagnosis program for dementia in primary care. J Gen Intern Med. 2005;20(7):572–7.PubMedCentralCrossRefPubMed
46.
Xiao LD, Wang J, He G-P, De Bellis A, Verbeeck J, Kyriazopoulos H. Family caregiver challenges in dementia care in Australia and China: a critical perspective. BMC Geriatr. 2014;14(1):6.PubMedCentralCrossRefPubMed
47.
Wu B, Carter MW, Goins RT, Cheng C. Emerging services for community-based long-term care in urban China: a systematic analysis of Shanghai’s community-based agencies. J Aging Soc Policy. 2005;17(4):37–60.CrossRefPubMed
48.
Li M, Zhang Y, Zhang Z, Zhang Y, Zhou L, Chen K. Rural-urban differences in the long-term care of the disabled elderly in China. PLoS One. 2013;8(11):e79955.PubMedCentralCrossRefPubMed
49.
Liu J, Wang L-N. Caregivers of patients with dementia in Chinese mainland: a retrospective analysis. Am J Alzheimers Dis Other Demen. 2013;28(7):679–81.CrossRefPubMed
50.
Feng Z, Liu C, Guan X, Mor V. China’s rapidly aging population creates policy challenges in shaping a viable long-term care system. Health Aff (Millwood). 2012;31(12):2764–73.CrossRef
51.
Prince M. Care arrangements for people with dementia in developing countries. Int J Geriatr Psychiatry. 2004;19(2):170–7.CrossRefPubMed
52.
Wang H, Gao T, Wimo A, Yu X. Caregiver time and cost of home care for Alzheimer’s disease: a clinic-based observational study in Beijing. China Ageing Int. 2010;35(2):153–65.CrossRef
53.
Li F, Wang F, Jia J. Evaluating the prevalence of dementia in hospitalized older adults and effects of comorbid dementia on patients’ hospital course. Aging Clin Exp Res. 2013;25(4):393–401.CrossRefPubMed
54.
Rudolph JL, Zanin NM, Jones RN, Marcantonio ER, Fong TG, Yang FM, et al. Hospitalization in community-dwelling persons with Alzheimer’s disease: frequency and causes. J Am Geriatr Soc. 2010;58(8):1542–8.PubMedCentralCrossRefPubMed
Metadata
Title
Clinical management and associated costs for moderate and severe Alzheimer’s disease in urban China: a Delphi panel study
Authors
Xin Yu
Shengdi Chen
Xiaochun Chen
Jianjun Jia
Chunhou Li
Cong Liu
Mondher Toumi
Dominique Milea
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Translational Neurodegeneration / Issue 1/2015
Electronic ISSN: 2047-9158
DOI
https://doi.org/10.1186/s40035-015-0038-9

Other articles of this Issue 1/2015

Translational Neurodegeneration 1/2015 Go to the issue

Research

Posttranslational modifications of α-tubulin in alzheimer disease

Research

No apparent transmission of transgenic α–synuclein into nigrostriatal dopaminergic neurons in multiple mouse models

Review

How to optimize the treatment of early stage Parkinson’s disease

Research

Meta-analyses on prevalence of selected Parkinson’s nonmotor symptoms before and after diagnosis

Review

New developments and future opportunities in biomarkers for amyotrophic lateral sclerosis

Review

Acid-sensing ion channels: potential therapeutic targets for neurologic diseases